392 related articles for article (PubMed ID: 32595502)
1. Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim.
Basu S; Lien YTK; Vozmediano V; Schlender JF; Eissing T; Schmidt S; Niederalt C
Front Pharmacol; 2020; 11():868. PubMed ID: 32595502
[TBL] [Abstract][Full Text] [Related]
2. Predictive Pediatric Modeling and Simulation Using Ontogeny Information.
Ince I; Solodenko J; Frechen S; Dallmann A; Niederalt C; Schlender J; Burghaus R; Lippert J; Willmann S
J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S95-S103. PubMed ID: 31502689
[TBL] [Abstract][Full Text] [Related]
3. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds.
Yun YE; Edginton AN
J Toxicol Environ Health A; 2019; 82(14):789-814. PubMed ID: 31405354
[TBL] [Abstract][Full Text] [Related]
4. Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients.
Kovar L; Weber A; Zemlin M; Kohl Y; Bals R; Meibohm B; Selzer D; Lehr T
Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 32977559
[TBL] [Abstract][Full Text] [Related]
5. Integration of Ontogeny Into a Physiologically Based Pharmacokinetic Model for Monoclonal Antibodies in Premature Infants.
Malik PRV; Edginton AN
J Clin Pharmacol; 2020 Apr; 60(4):466-476. PubMed ID: 31729044
[TBL] [Abstract][Full Text] [Related]
6. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
[TBL] [Abstract][Full Text] [Related]
7. Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization.
Zheng L; Xu M; Tang SW; Song HX; Jiang XH; Wang L
Pharm Res; 2019 Oct; 36(12):171. PubMed ID: 31654287
[TBL] [Abstract][Full Text] [Related]
8. A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim.
Niederalt C; Kuepfer L; Solodenko J; Eissing T; Siegmund HU; Block M; Willmann S; Lippert J
J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):235-257. PubMed ID: 29234936
[TBL] [Abstract][Full Text] [Related]
9. PBPK and its Virtual Populations: the Impact of Physiology on Pediatric Pharmacokinetic Predictions of Tramadol.
T'jollyn H; Vermeulen A; Van Bocxlaer J
AAPS J; 2018 Nov; 21(1):8. PubMed ID: 30498862
[TBL] [Abstract][Full Text] [Related]
10. Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population.
Maglalang PD; Sinha J; Zimmerman K; McCann S; Edginton A; Hornik CP; Hornik CD; Muller WJ; Al-Uzri A; Meyer M; Chen JY; Anand R; Perrin EM; Gonzalez D;
Clin Pharmacokinet; 2024 Jun; 63(6):885-899. PubMed ID: 38814425
[TBL] [Abstract][Full Text] [Related]
11. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.
Moj D; Britz H; Burhenne J; Stewart CF; Egerer G; Haefeli WE; Lehr T
Cancer Chemother Pharmacol; 2017 Nov; 80(5):1013-1026. PubMed ID: 28988277
[TBL] [Abstract][Full Text] [Related]
12. The use of PBPK modeling across the pediatric age range using propofol as a case.
Michelet R; Van Bocxlaer J; Allegaert K; Vermeulen A
J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):765-785. PubMed ID: 30298439
[TBL] [Abstract][Full Text] [Related]
13. Physiologically-Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients.
Malik PRV; Edginton AN
CPT Pharmacometrics Syst Pharmacol; 2019 Nov; 8(11):835-844. PubMed ID: 31343836
[TBL] [Abstract][Full Text] [Related]
14. Structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic (PBPK) model evaluation.
Ellison CA
Regul Toxicol Pharmacol; 2018 Nov; 99():61-77. PubMed ID: 30201539
[TBL] [Abstract][Full Text] [Related]
15. Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.
Khot A; Tibbitts J; Rock D; Shah DK
AAPS J; 2017 Nov; 19(6):1715-1734. PubMed ID: 28808917
[TBL] [Abstract][Full Text] [Related]
16. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children.
Centanni M; Zaher O; Elhad D; Karlsson MO; Friberg LE
Cancer Chemother Pharmacol; 2024 May; ():. PubMed ID: 38782791
[TBL] [Abstract][Full Text] [Related]
17. Translation of Monoclonal Antibodies Pharmacokinetics from Animal to Human Using Physiologically Based Modeling in Open Systems Pharmacology (OSP) Suite: A Retrospective Analysis of Bevacizumab.
Pasquiers B; Benamara S; Felices M; Ternant D; Declèves X; Puszkiel A
Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631343
[TBL] [Abstract][Full Text] [Related]
18. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach.
Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F
Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652
[TBL] [Abstract][Full Text] [Related]
19. Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents.
Pan X; Stader F; Abduljalil K; Gill KL; Johnson TN; Gardner I; Jamei M
AAPS J; 2020 May; 22(4):76. PubMed ID: 32449129
[TBL] [Abstract][Full Text] [Related]
20. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam.
Maharaj AR; Barrett JS; Edginton AN
AAPS J; 2013 Apr; 15(2):455-64. PubMed ID: 23344790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
